

Frederick S Buckner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1339393/publications.pdf>

Version: 2024-02-01

131
papers

6,339
citations

57631

44
h-index

79541

73
g-index

140
all docs

140
docs citations

140
times ranked

6905
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. <i>Nature</i> , 2016, 537, 229-233.	13.7	325
2	Genomic-scale prioritization of drug targets: the TDR Targets database. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 900-907.	21.5	282
3	Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. <i>Chemical Reviews</i> , 2014, 114, 11305-11347.	23.0	274
4	Identification of a Metabolically Stable Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Antimalarial Activity in Mice. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1864-1872.	2.9	228
5	Heterologous expression of proteins from <i>Plasmodium falciparum</i> : Results from 1000 genes. <i>Molecular and Biochemical Parasitology</i> , 2006, 148, 144-160.	0.5	173
6	<i>Toxoplasma gondii</i> calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 602-607.	3.6	172
7	Protein Farnesyltransferase Inhibitors Exhibit Potent Antimalarial Activity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3704-3713.	2.9	170
8	Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3935-3949.	2.9	156
9	Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1639-1647.	2.9	150
10	Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. <i>Molecular and Biochemical Parasitology</i> , 2003, 126, 155-163.	0.5	126
11	Adenosine Analogues as Selective Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase of <i>Trypanosomatida</i> via Structure-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2080-2093.	2.9	115
12	Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3887-3898.	2.9	107
13	Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation. <i>Journal of Lipid Research</i> , 2006, 47, 233-240.	2.0	104
14	Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. <i>Clinical Infectious Diseases</i> , 2020, 71, 2167-2173.	2.9	95
15	Hypertension Following Erythropoietin Therapy in Anemic Hemodialysis Patients. <i>American Journal of Hypertension</i> , 1990, 3, 947-955.	1.0	94
16	Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3710-3717.	1.4	86
17	The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. <i>Molecular and Biochemical Parasitology</i> , 1998, 94, 87-97.	0.5	85
18	Recent developments in sterol 14-demethylase inhibitors for Chagas disease. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2012, 2, 236-242.	1.4	85

#	ARTICLE	IF	CITATIONS
19	The Protein Farnesyltransferase Inhibitor Tipifarnib as a New Lead for the Development of Drugs against Chagas Disease. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5415-5418.	2.9	83
20	Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2977.	1.3	80
21	Selective Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against <i>Trypanosoma brucei</i> Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1982-1989.	1.4	75
22	Characterization of <i>Trypanosoma brucei</i> dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. <i>Molecular Microbiology</i> , 2008, 68, 37-50.	1.2	73
23	Potent Anti- <i>Trypanosoma cruzi</i> Activities of Oxidosqualene Cyclase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1210-1215.	1.4	72
24	Adenosine Analogues as Inhibitors of <i>Trypanosoma brucei</i> Phosphoglycerate Kinase: Elucidation of a Novel Binding Mode for a 2-Amino-N6-Substituted Adenosine. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4135-4150.	2.9	70
25	<i>Leishmania major</i> activates IL-1 β expression in macrophages through a MyD88-dependent pathway. <i>Microbes and Infection</i> , 2002, 4, 763-771.	1.0	70
26	Detection of Live <i>Trypanosoma cruzi</i> in Tissues of Infected Mice by Using Histochemical Stain for β -Galactosidase. <i>Infection and Immunity</i> , 1999, 67, 403-409.	1.0	70
27	Distinct States of Methionyl-tRNA Synthetase Indicate Inhibitor Binding by Conformational Selection. <i>Structure</i> , 2012, 20, 1681-1691.	1.6	69
28	Induction of Resistance to Azole Drugs in <i>Trypanosoma cruzi</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 3245-3250.	1.4	68
29	Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold To Identify the Minimum Pharmacophore Required for Inhibitory Activity against <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7425-7436.	2.9	67
30	Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 828-835.	2.9	67
31	Using Fragment Cocktail Crystallography To Assist Inhibitor Design of <i>Trypanosoma brucei</i> Nucleoside 2-Deoxyribosyltransferase. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5939-5946.	2.9	66
32	Second Generation Tetrahydroquinoline-Based Protein Farnesyltransferase Inhibitors as Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4585-4605.	2.9	66
33	A class of sterol 14-demethylase inhibitors as anti- <i>Trypanosoma cruzi</i> agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15149-15153.	3.3	65
34	Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular <i>Trypanosoma cruzi</i> by Chemical Library Screening. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e384.	1.3	63
35	Advances in Chagas disease drug development: 2009–2010. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 609-616.	1.3	60
36	Urea-Based Inhibitors of <i>Trypanosoma brucei</i> Methionyl-tRNA Synthetase: Selectivity and in Vivo Characterization. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6342-6351.	2.9	60

#	ARTICLE	IF	CITATIONS
37	Protein Farnesyltransferase from <i>Trypanosoma brucei</i> . <i>Journal of Biological Chemistry</i> , 1998, 273, 26497-26505.	1.6	58
38	Cloning, Heterologous Expression, and Distinct Substrate Specificity of Protein Farnesyltransferase from <i>Trypanosoma brucei</i> . <i>Journal of Biological Chemistry</i> , 2000, 275, 21870-21876.	1.6	55
39	Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from <i>Trypanosoma cruzi</i> and <i>Leishmania major</i> . <i>Molecular and Biochemical Parasitology</i> , 2002, 122, 181-188.	0.5	53
40	<i>Leishmania</i> inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. <i>Transfusion</i> , 2005, 45, 1459-1463.	0.8	52
41	Structure of <i>Leishmania major</i> methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. <i>Biochimie</i> , 2011, 93, 570-582.	1.3	50
42	Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4914-4921.	1.4	50
43	Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti- <i>Trypanosoma brucei</i> Agents. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 432-445.	2.9	49
44	COLORIMETRIC ASSAY FOR SCREENING COMPOUNDS AGAINST LEISHMANIA AMASTIGOTES GROWN IN MACROPHAGES. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 72, 600-605.	0.6	49
45	Sterol 14-Demethylase Inhibitors for <i>Trypanosoma cruzi</i> Infections. <i>Advances in Experimental Medicine and Biology</i> , 2008, 625, 61-80.	0.8	47
46	Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 957-971.	2.9	47
47	In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 6517-6526.	1.4	45
48	Heterologous expression of <i>L. major</i> proteins in <i>S. cerevisiae</i> : a test of solubility, purity, and gene recoding. <i>Journal of Structural and Functional Genomics</i> , 2009, 10, 233-247.	1.2	43
49	Buffer Optimization of Thermal Melt Assays of Plasmodium Proteins for Detection of Small-Molecule Ligands. <i>Journal of Biomolecular Screening</i> , 2009, 14, 700-707.	2.6	42
50	Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of <i>Plasmodium falciparum</i> Protein Farnesyltransferase. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3659-3671.	1.4	40
51	The Double-Length Tyrosyl-tRNA Synthetase from the Eukaryote <i>Leishmania major</i> Forms an Intrinsically Asymmetric Pseudo-Dimer. <i>Journal of Molecular Biology</i> , 2011, 409, 159-176.	2.0	40
52	Trypanosome and Animal Lanosterol Synthases Use Different Catalytic Motifs. <i>Organic Letters</i> , 2001, 3, 1957-1960.	2.4	39
53	Altered sterol profile induced in <i>Leishmania amazonensis</i> by a natural dihydroxymethoxylated chalcone. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 469-472.	1.3	39
54	Structurally Simple Inhibitors of Lanosterol 14 α -Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3703-3715.	2.9	38

#	ARTICLE	IF	CITATIONS
55	Structural Genomics of Pathogenic Protozoa: an Overview. <i>Methods in Molecular Biology</i> , 2008, 426, 497-513.	0.4	38
56	Structurally Simple Farnesyltransferase Inhibitors Arrest the Growth of Malaria Parasites. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 4903-4906.	7.2	37
57	Crystal Structures of Trypanosomal Histidyl-tRNA Synthetase Illuminate Differences between Eukaryotic and Prokaryotic Homologs. <i>Journal of Molecular Biology</i> , 2010, 397, 481-494.	2.0	37
58	Structures of <i>Trypanosoma brucei</i> Methionyl-tRNA Synthetase with Urea-Based Inhibitors Provide Guidance for Drug Design against Sleeping Sickness. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2775.	1.3	37
59	Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of <i>Cryptosporidium</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	37
60	Structurally Simple, Potent, Plasmodium Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5710-5727.	2.9	36
61	Fragment-Based Cocktail Crystallography by the Medical Structural Genomics of Pathogenic Protozoa Consortium. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1678-1687.	1.0	36
62	Identification of Potent Inhibitors of the <i>Trypanosoma brucei</i> Methionyl-tRNA Synthetase via High-Throughput Orthogonal Screening. <i>Journal of Biomolecular Screening</i> , 2015, 20, 122-130.	2.6	35
63	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from <i>Plasmodium falciparum</i> at 2.25 Å... resolution reveals intriguing extra electron density in the active site. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 62, 570-577.	1.5	34
64	Delusional parasitosis: six-year experience with 23 consecutive cases at an academic medical center. <i>International Journal of Infectious Diseases</i> , 2010, 14, e317-e321.	1.5	34
65	Oxidosqualene Cyclase Inhibitors as Antimicrobial Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4240-4243.	2.9	33
66	Potent, Plasmodium-Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites: Structure-Activity Relationships of Ethylenediamine-Analogue Scaffolds and Homology Model Validation. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5176-5197.	2.9	33
67	Structures of Substrate- and Inhibitor-Bound Adenosine Deaminase from a Human Malaria Parasite Show a Dramatic Conformational Change and Shed Light on Drug Selectivity. <i>Journal of Molecular Biology</i> , 2008, 381, 975-988.	2.0	33
68	Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 791-7.	2.3	33
69	TcRho1, a Farnesylated Rho Family Homologue from <i>Trypanosoma cruzi</i> . <i>Journal of Biological Chemistry</i> , 2001, 276, 29711-29718.	1.6	31
70	Isothiazole dioxides: synthesis and inhibition of <i>Trypanosoma brucei</i> protein farnesyltransferase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2217-2220.	1.0	28
71	5-Fluoroimidazo[4,5- <i>b</i>]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors. <i>ACS Infectious Diseases</i> , 2016, 2, 399-404.	1.8	28
72	Crystal structures of <i>Plasmodium falciparum</i> cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design. <i>Molecular and Biochemical Parasitology</i> , 2013, 189, 26-32.	0.5	27

#	ARTICLE	IF	CITATIONS
73	1-Benzyl-3-aryl-2-thiohydantoin Derivatives as New Anti- <i>Trypanosoma brucei</i> Agents: SAR and in Vivo Efficacy. ACS Medicinal Chemistry Letters, 2017, 8, 886-891.	1.3	27
74	Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. American Journal of Tropical Medicine and Hygiene, 2005, 72, 600-5.	0.6	27
75	Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene. Molecular and Biochemical Parasitology, 2000, 110, 399-403.	0.5	25
76	C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Molecular and Biochemical Parasitology, 2007, 153, 115-124.	0.5	25
77	Experimental Chemotherapy and Approaches to Drug Discovery for Trypanosoma cruzi Infection. Advances in Parasitology, 2011, 75, 89-119.	1.4	25
78	Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 1081-1092.	2.6	25
79	Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	25
80	Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Molecular and Biochemical Parasitology, 2005, 144, 68-75.	0.5	24
81	Expression of mammalian cytokines by Trypanosoma cruzi indicates unique signal sequence requirements and processing. Molecular and Biochemical Parasitology, 1995, 75, 25-31.	0.5	22
82	Recent highlights in anti-protozoan drug development and resistance research. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 230-235.	1.4	22
83	Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Giardia intestinalis Trophozoites. Antimicrobial Agents and Chemotherapy, 2015, 59, 7128-7131.	1.4	21
84	New Class of Antitrypanosomal Agents Based on Imidazopyridines. ACS Medicinal Chemistry Letters, 2017, 8, 766-770.	1.3	21
85	Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. PLoS ONE, 2016, 11, e0160350.	1.1	21
86	Induced Resistance to Methionyl-tRNA Synthetase Inhibitors in Trypanosoma brucei Is Due to Overexpression of the Target. Antimicrobial Agents and Chemotherapy, 2013, 57, 3021-3028.	1.4	19
87	A binding hotspot in <i>Trypanosoma cruzi</i> histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 1684-1698.	2.5	19
88	From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis. ACS Infectious Diseases, 2017, 3, 225-236.	1.8	19
89	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis. ACS Medicinal Chemistry Letters, 2019, 10, 105-110.	1.3	19
90	High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay. Indian Journal of Experimental Biology, 2009, 47, 475-9.	0.5	19

#	ARTICLE	IF	CITATIONS
91	Centrally Administered Inhibitors of the Generation and Action of Angiotensin II Do Not Attenuate the Increase in ACTH Secretion Produced by Ether Stress in Rats. <i>Neuroendocrinology</i> , 1986, 42, 97-101.	1.2	18
92	Cloning and analysis of <i>Trypanosoma cruzi</i> lanosterol 14 α -demethylase. <i>Molecular and Biochemical Parasitology</i> , 2003, 132, 75-81.	0.5	18
93	<i>Trypanosoma cruzi</i> infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 1997, 27, 2541-2548.	1.6	17
94	Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti- <i>Trypanosoma cruzi</i> agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6582-6584.	1.0	17
95	Prediction of protein crystallization outcome using a hybrid method. <i>Journal of Structural Biology</i> , 2010, 171, 64-73.	1.3	17
96	Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , 2020, 6, 3-13.	1.8	17
97	The Crystal Structure and Activity of a Putative Trypanosomal Nucleoside Phosphorylase Reveal It to be a Homodimeric Uridine Phosphorylase. <i>Journal of Molecular Biology</i> , 2010, 396, 1244-1259.	2.0	16
98	Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. <i>Molecular and Biochemical Parasitology</i> , 2011, 177, 20-28.	0.5	16
99	Synthesis and Structure-Activity Relationships of Imidazopyridine/Pyrimidine- and Furopyridine-Based Anti-infective Agents against Trypanosomiases. <i>ChemMedChem</i> , 2021, 16, 966-975.	1.6	16
100	Protein geranylgeranyltransferase-I of <i>Trypanosoma cruzi</i> . <i>Molecular and Biochemical Parasitology</i> , 2008, 157, 32-43.	0.5	14
101	Crystal structure of the aspartyl-tRNA synthetase from <i>Entamoeba histolytica</i> . <i>Molecular and Biochemical Parasitology</i> , 2010, 169, 95-100.	0.5	14
102	Optimization of a binding fragment targeting the "enlarged methionine pocket" leads to potent <i>Trypanosoma brucei</i> methionyl-tRNA synthetase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2702-2707.	1.0	14
103	Structure of ribose 5-phosphate isomerase from <i>Plasmodium falciparum</i> . <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2006, 62, 427-431.	0.7	13
104	<i>Leishmania donovani</i> tyrosyl-tRNA synthetase structure in complex with a tyrosyl adenylate analog and comparisons with human and protozoan counterparts. <i>Biochimie</i> , 2017, 138, 124-136.	1.3	13
105	<i>Trypanosoma cruzi</i> : Expression of Interleukin-2 Utilizing both Supercoiled Plasmids and Linear DNAs. <i>Experimental Parasitology</i> , 1996, 83, 159-163.	0.5	12
106	The structure of tryptophanyl-tRNA synthetase from <i>Giardia lamblia</i> reveals divergence from eukaryotic homologs. <i>Journal of Structural Biology</i> , 2010, 171, 238-243.	1.3	12
107	Bioactivity of Farnesyltransferase Inhibitors Against <i>Entamoeba histolytica</i> and <i>Schistosoma mansoni</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 180.	1.8	12
108	Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against <i>Trypanosoma brucei</i> . <i>RSC Medicinal Chemistry</i> , 2020, 11, 885-895.	1.7	12

#	ARTICLE	IF	CITATIONS
109	Methionyl-tRNA synthetase inhibitor has potent <i>in vivo</i> activity in a novel <i>Giardia lamblia</i> luciferase murine infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1218-1227.	1.3	12
110	Spontaneous Selection of <i>Cryptosporidium</i> Drug Resistance in a Calf Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	12
111	Dialkylimidazole inhibitors of <i>Trypanosoma cruzi</i> sterol 14 α -demethylase as anti-Chagas disease agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6492-6499.	1.0	11
112	<i>Trypanosoma cruzi</i> : Use of Herpes Simplex Virus θ Thymidine Kinase as a Negative Selectable Marker. <i>Experimental Parasitology</i> , 1997, 86, 171-180.	0.5	10
113	Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent <i>Trypanosoma brucei</i> inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1571-1584.	1.4	10
114	The crystal structure of the drug target <i>Mycobacterium tuberculosis</i> methionyl-tRNA synthetase in complex with a catalytic intermediate. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2018, 74, 245-254.	0.4	10
115	<i>Trypanosoma brucei</i> prenylated-protein carboxyl methyltransferase prefers farnesylated substrates. <i>Biochemical Journal</i> , 2002, 367, 809-816.	1.7	9
116	Structure of the conserved hypothetical protein MAL13P1.257 from <i>Plasmodium falciparum</i> . <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2006, 62, 180-185.	0.7	9
117	Screening a fragment cocktail library using ultrafiltration. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1585-1591.	1.9	9
118	Structure of the prolyl-tRNA synthetase from the eukaryotic pathogen <i>Giardia lamblia</i> . <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2012, 68, 1194-1200.	2.5	9
119	Differential drug binding by the highly conserved <i>Plasmodium falciparum</i> thymidylate synthase. <i>Molecular and Biochemical Parasitology</i> , 2005, 143, 121-124.	0.5	7
120	Cloning and functional characterization of a <i>Trypanosoma brucei</i> lanosterol 14 α -demethylase gene. <i>Molecular and Biochemical Parasitology</i> , 2001, 117, 115-117.	0.5	6
121	Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 23.	0.9	6
122	The structure of <i>Plasmodium vivax</i> phosphatidylethanolamine-binding protein suggests a functional motif containing a left-handed helix. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2007, 63, 178-182.	0.7	5
123	Structure of a <i>Trypanosoma brucei</i> β -hydrolase fold protein with unknown function. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2008, 64, 474-478.	0.7	5
124	Confirmation of Chagas' cardiomyopathy following heart transplantation. <i>Heart and Vessels</i> , 2006, 21, 325-327.	0.5	4
125	An Essential Farnesylated Kinesin in <i>Trypanosoma brucei</i> . <i>PLoS ONE</i> , 2011, 6, e26508.	1.1	4
126	A new chemotype with promise against <i>Trypanosoma cruzi</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126778.	1.0	1

#	ARTICLE	IF	CITATIONS
127	Early Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads. ACS Infectious Diseases, 2021, 7, 1874-1876.	1.8	1
128	Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis. American Journal of Tropical Medicine and Hygiene, 2021, 105, 142-143.	0.6	1
129	A 71-year-old man with recurrent pulmonary mycobacterial avium complex infections and lymphopenia. Allergy and Asthma Proceedings, 2020, 41, 66-69.	1.0	1
130	Immunological Aspects of Cardiac Disease. , 0, , 199-230.		0
131	The Tryp and the Pendulum. EBioMedicine, 2021, 64, 103188.	2.7	0